FR2621817A1 - DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED - Google Patents
DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED Download PDFInfo
- Publication number
- FR2621817A1 FR2621817A1 FR8714345A FR8714345A FR2621817A1 FR 2621817 A1 FR2621817 A1 FR 2621817A1 FR 8714345 A FR8714345 A FR 8714345A FR 8714345 A FR8714345 A FR 8714345A FR 2621817 A1 FR2621817 A1 FR 2621817A1
- Authority
- FR
- France
- Prior art keywords
- spraying
- drug
- nasal
- polymyxin
- tobramycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
La présente invention concerne un médicament pour vaporisation destiné à prévenir les risques dtinfection chez les malades à risques en décontaminant les cavités nasales et oropharyngées
Les infections à bacilles gram négatif et les mycoses sont fréquentes chez les malades à risques . Elles entraînent une morbidité importante , elles sont une des causes principales du décès de ces patients , elles augmentent les dépenses de santé en augmentant les durées d'hospitalisation
La présente invention permet de remédier à cet inconvénient . Elle comporte l'associatign de trois antibiotiques administrée par vaporisation dans les cavités nasales et orophryngées . Les trois antibiotiques associés dans la préparation sont la polymyxine B , la tobramycine et l'amphotéricine B .La préparation doit adhérer aux muqueuses nasales et buccales , relarguer lentement les antibiotiques et avoir une tension superficielle permettant un talement maximal sur les muqueuses nasales et oropharyngées . La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise . Deux poussoirs sont fournis avec chaque flacon :: l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fosses nasales , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée
Les doses distribuées par les valves ou les pompes seront très précises
Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation
La fréquence des applications dépend également de la concentration de ces produits.The present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase healthcare costs by increasing hospital stays
The present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and orophryngeal cavities. The three antibiotics associated in the preparation are polymyxin B, tobramycin and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing a maximum talement on the nasal and oropharyngeal mucous membranes. The preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump. Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and vaporization of the nasal cavities, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity
The doses distributed by the valves or the pumps will be very precise
They are of course a function of the concentration of antibiotics within the preparation
The frequency of applications also depends on the concentration of these products.
Aucun de ces antibiotiques n'étant absorbé par voie nasale , oropharyngée ou digestive , les posologies et donc les concentrations peuvent varier dans une très large part
Les caractéristiques et avantages de l'invention ressortent de la description qui va suivre à titre d'exemple : pour 30 ml de préparation , on associe
-sulfate de polymyxine B : 500 mg
-sulfate de tobramycine : 450 mg
-amphotéricine B : 2500 mg
-alcool à 900 : 1 ml
-saccharinate de sodium : 100 mg
-essence de menthe : 0,02ml
-glycérine : quantité suffisante
pour 30 ml
La valve ou la pompe doit être adaptée pour délivrer 0,5 ml à chaque pres sion . On recommande 6 pressions dans la cavité oropharyngée , 3 pressions dans chaque narine à chaque administration et une fréquence de quatre administrations par jour . Dans cet exemple , on administre 400 mg de polymyxine
B ,360 mg de tobramycine et 2000 mg d' amphotéricine B par jour
ilest recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par
s sonde gastrique avec ces même antibiotiques même antibiotiques
Les indications de ce médicament sont très larges : ildoit être employé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent: en réanimation , en hématologie , en chirurgie, en anesthésiologie , en cancérologie , etc... None of these antibiotics being absorbed via the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
The characteristics and advantages of the invention appear from the description which follows by way of example: for 30 ml of preparation, one associates
-polymyxin B sulfate: 500 mg
-tobramycin sulfate: 450 mg
-amphotericin B: 2500 mg
- 900 alcohol: 1 ml
-sodium saccharinate: 100 mg
-mint essence: 0.02ml
-glycerin: sufficient amount
for 30 ml
The valve or pump must be adapted to deliver 0.5 ml at each pressure. We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril with each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin is administered
B, 360 mg tobramycin and 2000 mg amphotericin B per day
it is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by
s gastric tube with these same antibiotics same antibiotics
The indications for this drug are very broad: it must be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc ...
Claims (3)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8714345A FR2621817B1 (en) | 1987-10-19 | 1987-10-19 | DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED |
EP19880909559 EP0338062A1 (en) | 1987-10-19 | 1988-10-19 | Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying |
PCT/FR1988/000513 WO1989003673A1 (en) | 1987-10-19 | 1988-10-19 | Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying |
AU26140/88A AU2614088A (en) | 1987-10-19 | 1988-10-19 | Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8714345A FR2621817B1 (en) | 1987-10-19 | 1987-10-19 | DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2621817A1 true FR2621817A1 (en) | 1989-04-21 |
FR2621817B1 FR2621817B1 (en) | 1990-12-14 |
Family
ID=9355910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR8714345A Expired - Lifetime FR2621817B1 (en) | 1987-10-19 | 1987-10-19 | DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0338062A1 (en) |
AU (1) | AU2614088A (en) |
FR (1) | FR2621817B1 (en) |
WO (1) | WO1989003673A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2290707A (en) * | 1994-06-28 | 1996-01-10 | Georgi Stankov | Pharmaceutical uses of Amphotericin B |
GB2290708A (en) * | 1994-06-28 | 1996-01-10 | Georgi Stankov | Pharmaceutical uses of polyene macrolides |
EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
JP5670421B2 (en) | 2009-03-31 | 2015-02-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Component surface coating method |
EP2432531B1 (en) | 2009-05-18 | 2019-03-06 | Boehringer Ingelheim International GmbH | Adapter, inhalation device and nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
JP5715640B2 (en) | 2009-11-25 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nebulizer |
EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
EP2694220B1 (en) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medical device comprising a container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
WO2013152894A1 (en) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Atomiser with coding means |
ES2836977T3 (en) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizer |
EP3030298B1 (en) | 2013-08-09 | 2017-10-11 | Boehringer Ingelheim International GmbH | Nebulizer |
CN106232166B (en) | 2014-05-07 | 2020-04-14 | 勃林格殷格翰国际有限公司 | Sprayer with a spray tube |
PL3139984T3 (en) | 2014-05-07 | 2021-11-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
CN106255554B (en) | 2014-05-07 | 2021-05-04 | 勃林格殷格翰国际有限公司 | Container, sprayer and use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL121455C (en) * | 1900-01-01 | |||
GB1018125A (en) * | 1962-11-29 | 1966-01-26 | Merck & Co Inc | Chemical products |
AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
-
1987
- 1987-10-19 FR FR8714345A patent/FR2621817B1/en not_active Expired - Lifetime
-
1988
- 1988-10-19 WO PCT/FR1988/000513 patent/WO1989003673A1/en not_active Application Discontinuation
- 1988-10-19 EP EP19880909559 patent/EP0338062A1/en not_active Ceased
- 1988-10-19 AU AU26140/88A patent/AU2614088A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL121455C (en) * | 1900-01-01 | |||
GB1018125A (en) * | 1962-11-29 | 1966-01-26 | Merck & Co Inc | Chemical products |
AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
Non-Patent Citations (1)
Title |
---|
"The Merck Index", édition 10, 1983, pages 85,1093,1358, Merck & Co., Rahway, NJ, US * |
Also Published As
Publication number | Publication date |
---|---|
WO1989003673A1 (en) | 1989-05-05 |
FR2621817B1 (en) | 1990-12-14 |
AU2614088A (en) | 1989-05-23 |
EP0338062A1 (en) | 1989-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2621817A1 (en) | DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED | |
FR2624015A1 (en) | MEDICINE COMPRISING THE COMBINATION OF COLISTINE, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED | |
FR2621818A1 (en) | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION | |
ES2330415T3 (en) | SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS. | |
CA2039456A1 (en) | Osmotic dosage system for liquid drug delivery | |
KR880013586A (en) | Dosage device comprising a removable substrate with a solid state property | |
DK0998916T3 (en) | Medicines for administration to the mucosa | |
KR880002502A (en) | Formulations for Administration of Beneficial Acid Sensitive Agents | |
WO2000022909A3 (en) | Systems for oral delivery | |
ES2104522T3 (en) | NEW MEDICINAL ADMINISTRATION SYSTEM. | |
ATE138071T1 (en) | LIPID AIDS FOR ADMINISTRATION THROUGH THE NOSE AND TOPICAL APPLICATION | |
US4876283A (en) | Antisnoring agent | |
PT984762E (en) | DEBIT CONTROLLER CONFIGURATIONS FOR AN ACTIVE AGENT ADMINISTRATION DEVICE | |
ES2171469T3 (en) | COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT. | |
CA1223210A (en) | Antisnoring agent | |
CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
KR970032872A (en) | Drugs for the treatment of skin damage containing acetylsalicylic acid | |
FR2624017A1 (en) | Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation | |
FR2622113A1 (en) | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation | |
JP2002068963A (en) | Liquid agent and container | |
FR2624738A1 (en) | Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation | |
FR2624739A1 (en) | Medicament comprising a combination of colistin, neomycin and amphotericin B administered by vaporisation | |
FR2622107A1 (en) | Medicament comprising a combination of polymyxin B, sissomicin and amphotericin B administered by vaporisation | |
FR2622111A1 (en) | Medicament comprising a combination of polymyxin B, dibekacin and amphotericin B administered by vaporisation | |
FR2624740A1 (en) | Medicament comprising a combination of colistin, dibekacin and amphotericin B administered by vaporisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |